MGMT and glioblastoma: Further efforts to improve chemotherapy efficacy include the addition of Lomustine to TMZ in patients with MGMT-methylated glioblastoma, resulting in median survival benefits of 48.1 months versus 31.4 months in a recent phase III clinical trial (16), albeit with increased toxicity.